Generated by AI
ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease. The company’s work centers on proprietary autologous cell therapy platforms designed to support kidney function in patients with advanced kidney disease and diabetes. Its lead therapeutic program is directed at treating moderate to severe diabetic kidney disease and other chronic kidney conditions, placing ProKidney in the broader renal therapeutics sector. The company’s current business is concentrated on research, clinical development, and the advancement of its cell therapy candidates, making it a specialized participant in the biotechnology market. ProKidney Corp. is headquartered in Winston-Salem, North Carolina, and its Class A ordinary shares are one of the company’s publicly traded equity classes.
Website2000 Frontis Plaza Boulevard
Winston-Salem, NC, 27103
United States
The latest articles about PROK.
Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.
Summary of May 28's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Summary of Jul 10's posts. Generated by AI.
No summary yet.
Summary of Sep 12's posts. Generated by AI.
Investors talking about PROK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.